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Abstract
Background:  The aim of this study was to evaluate gene therapy for AIDS based on the
transduction of circulating lymphocytes with a retroviral vector giving low levels of constitutive
macaque interferon β production in macaques chronically infected with a pathogenic isolate of
SIVmac251.
Results: Two groups of three animals infected for more than one year with a pathogenic primary
isolate of SIVmac251 were included in this study. The macaques received three infusions of their
own lymphocytes transduced ex vivo with the construct encoding macaque IFN-β (MaIFN-β or
with a vector carrying a version of the MaIFN-β gene with a deletion preventing translation of the
mRNA. Cellular or plasma viremia increased transiently following injection in most cases,
regardless of the retroviral construct used. Transduced cells were detected only transiently after
each infusion, among the peripheral blood mononuclear cells of all the animals, with copy numbers
of 10 to 1000 per 106 peripheral mononuclear cells.
Conclusion: Long-term follow-up indicated that the transitory presence of such a small number
of cells producing such small amounts of MaIFN-β did not prevent animals from the progressive
decrease in CD4+ cell count typical of infection with simian immunodeficiency virus. These results
reveal potential pitfalls for future developments of gene therapy strategies of HIV infection.
Background
Highly active antiretroviral therapy (HAART) effectively
inhibits human immunodeficiency virus (HIV) replica-
tion, but it has been suggested that a combination of
HAART and strategies for boosting the immune system
would give more effective long-term control of HIV
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infection [1,2]. Interferon β (IFN-β) is an attractive candi-
date for such therapy: 1) it is a natural, potent antiviral
protein that inhibits HIV at various stages of the viral
cycle, from uptake to the release of virus particles [3-9]; 2)
Type I IFNs display immunomodulatory properties that
could improve the immune control of HIV replication
[10-12].
During HIV infection, the induction of type I IFN produc-
tion has been shown to be impaired in T cells and macro-
phages, which are considered to be the major targets of
the virus [13-16]. However, the use of recombinant IFN in
therapeutic strategies is limited by its poor bioavailability
and the need for high doses to obtain an antiviral effect,
resulting in deleterious side effects [17].
It has been suggested that the efficacy of type I IFNs for the
treatment of HIV infection could be increased by develop-
ing a gene therapy strategy based on the modified produc-
tion of IFN-β in genetically engineered lymphocytes [18].
For this purpose, a retroviral vector derived from Moloney
murine leukemia virus, in which the human IFN-β coding
sequence has been placed under the control of a fragment
of the murine H2-Kb gene promoter, has been used to
ensure the continuous generation of low levels of IFN-β in
transduced cells [10,19]. The transduction of peripheral
blood lymphocytes (PBL) with this vector inhibits HIV
replication in vitro and increases the survival of CD4+ cells
in culture. Furthermore, IFN-β production in PBL from
HIV-infected donors increases Th1-type cytokine produc-
tion, improves cytotoxic responses against cells expressing
HIV proteins, and the proliferative response to recall anti-
gens [10,12]. These in vitro results have been confirmed in
the SCID mouse model of HIV infection [20]. However, as
the human-SCID mouse has a number of limitations as a
model of AIDS, the efficacy and safety of this strategy
should also be evaluated in a more appropriate model,
such as macaques infected with simian immunodefi-
ciency virus (SIV).
SIV resembles HIV-1 and HIV-2 in its genomic organiza-
tion and biological properties [21] and systematically
causes a disease in macaques that is remarkably similar to
AIDS in humans [22]. We have previously shown that PBL
obtained from seronegative animals and transduced with
a vector carrying the macaque IFN-β coding sequence
placed under the control of a 0.6-kb fragment of the
murine H2-Kb gene promoter develop greater resistance to
SIVmac251 in vitro [23]. In healthy seronegative
macaques, infusion with autologous lymphocytes trans-
duced ex vivo with the vector encoding IFN-β results in
approximately 1 transduced cell per thousand peripheral
blood mononuclear cells (PBMCs). The genetically modi-
fied cells were detected for at least 74 days after infusion,
with no major side effects, in these experiments. Follow-
ing infection with SIVmac251, macaques that had
received the IFN-β construct infusion displayed lower
peak plasma viral loads during primary infection than did
control macaques. No adverse reaction was observed, and
these macaques maintained high CD4+ T-lymphocyte
counts for at least 478 days [24].
However, a gene therapy strategy for HIV infection would
only be possible during the chronic phase of infection. At
this stage, the immune system, and particularly CD4+ T
cells – the major target of our gene therapy approach –
may be strongly affected by the virus. We therefore inves-
tigated the safety and efficacy of this strategy in macaques
chronically infected with a primary, pathogenic isolate of
SIVmac251, but still in an asymptomatic state. The effi-
cacy of our strategy has been examined according to two
parameters. The eventual survival advantage of IFN-β
transduced cells has been monitored by following the
presence of such transduced cells in the blood stream as
well as in the lymph nodes of infused macaques. This
group of animals was compared to a controlgroup having
received cells transduced with a retrovirus carrying a mod-
ified version of the MaIFN  sequence with a deletion
blocking mRNA translation. Animals were subjected to
three infusions of autologous T lymphocytes transduced
ex vivo with both constructs. The eventual clinical benefits
of the presence of IFN-β-transduced cells have been mon-
itored for two years, by examining, in both groups of ani-
mals, the absolute number of circulating CD4+
lymphocytes, cell associated viral load and plasma vial
load.
Results
Status of animals before treatment
The in vivo safety and anti-SIV efficacy of IFN-β-engi-
neered lymphocytes in chronically SIV-infected macaques
was assessed by following for two years animals that had
received three infusions day 0, day 361 and day 613) of
autologous T lymphocytes transduced with a construct
encoding IFN-β (macaques IFN1, IFN2, IFN3) or, as a
control, with a retrovirus carrying a modified version of
the IFN-β that could not generate functional protein
(macaques C1, C2, C3). These macaques had been
infected with 4 AID50 of a primary, pathogenic isolate of
SIVmac251 more than one year before the start of the
experiment. On day 0, the mean number of circulating
CD4+ T lymphocytes was 767 ± 215 µl, and all animals
had detectable SIV provirus in PBMCs (Table 1). Plasma
SIV viremia was low or undetectable in most animals, the
detection threshold being 1,500 copies of SIV RNA copies
per milliliter of plasma.
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Transduced PBLs
After being transduced with the MFG-KbMaIFN-β and
MFG-Kb∆MaIFN-β constructs, PBLs were readministered
to the animal from which they were originally taken. Each
macaque was infused with 108 to 4 × 108 lymphocytes.
Semi-quantitative PCR analysis revealed that the mean
transduction efficiencies for the transduction of PBL with
the MFG-KbMaIFN-β and MFG-Kb∆MaIFN-β constructs
were 10.33 % ± 7.42 % and 17.13 % ± 10.61 %, respec-
tively. The IFN-β-transduced populations were character-
ized in culture by a low IFN-β production, ranging from
12 to 24 units per 5 × 105 cells per 3 days.
We previously published that similar rates of Ma IFN-β-
transduction results in a signficant reduction of
SIVmac251 replication in vitro [23]. Such IFN-β-trans-
duced cells remain detectable in the blood stream 485
days after reinfusion [24].
After the first inoculation (day 0), transduced cells was
detected in peripheral blood, with about 10 transduced
cells per 106 cells, for 14 days in macaque IFN1, and for 29
days in macaques IFN3 and C2 (Table 2). A transient peak
of 1000 and 700 transduced cells per 106 circulating cells
was observed in macaques C1 and C3, respectively. After
completion of the series of infusions, with the last infu-
sion occurring on day 613, transduced cells persisted at a
low level (10 transduced cells per 106 cells) for only up to
60 days (Table 2). No transduced cells were detected at
any time in the study for macaque IFN2. No significant
difference was observed between the two groups of
macaques in terms of transduced cell persistence (Table
2). The frequency of transduced cells was similar for CD4+
and CD8+ lymphocytes analyzed on day 673 (data not
shown). No retroviral construct was detected in lymph
nodes and splenic mononuclear cells.
Clinical status and immunological follow-up
Weight and rectal temperature remained fairly constant
throughout the study (data not shown). No major varia-
tion in classical hematological parameters, including total
lymphocyte and platelets counts, and hemoglobin con-
centration, was observed (data not shown).
Immunological follow-up indicated that seven days after
the first infusion (day 0), the number of circulating CD4+
lymphocytes significantly increased in all macaques stud-
ied (p < 0.05), except for C3. A similar significant increase
(p < 0.05) was observed in the days following the second
infusion (on day 311) for macaques IFN2, and C1, and
following the third infusion (on day 613) for macaques
IFN1, and C1 (Fig. 1A – 2A).
For all animals in both groups, absolute numbers of
CD4+ T cells gradually decreased during the study (p <
0.05), and no significant difference in absolute numbers
of CD4+ T cells was observed between the two groups of
macaques (Fig. 1A – 2A).
Table 1: Immunological and virological parameters of macaques at day 0 of the experiment. At the onset of the experiment, the six 
male cynomolgus macaques (Macaca fascicularis) were chronically infected by 4 AID 50 of a primary and pathogenic isolate of 
SIVmac251 for more than one year. They have been characterized for their mean number of circulating CD4+ T-lymphocytes, the time 
after SIV inoculation, and the cellular and plasma SIV viral loads. IFN group is represented by the three macaques that received their 
own cells transduced by the biologically active construct of IFN-β gene whereas the control group is represented by the three macaques 
that received their own cells transduced by the control construct. a: Immunophenotyping of Ficoll-purified PBMCs was performed by 
immunostaining with specific anti-CD4 and anti-CD8 antibodies, and analyzing by flow cytometry. The mean number of circulating 
CD4+ T-lymphocytes was determined at day 0 post first infusion with five points preceeding the onset of the experiment. b: Cellular 
viral load was estimated by a quantitative limit dilution nested PCR method allowing specific double amplification of a gagfragment of 
SIVmac251. Number of proviral copies was estimated by the last dilution that can display, in an agarose gel, a signal amplification. The 
number of SIVmac251 gag gene copies per 1 mg of DNA, for instance 131300 cells, was then brought back to a number of gene copies 
per 106 cells. c Plasma SIV viral load was determined by the branched-DNA method.
Mean number of 
circulating CD4+ 
lymphocytes a
Time after inoculation 
of SIVmac251
Mean number of SIV 
proviral DNA copies 
in PBMCs b (Copies 
per 106 cells)
Plasma SIV load c(103 
copies per ml)
Mean +/- Standard 
Deviation
Days Mean +/- Standard 
Deviation
IFN IFN1 811 +/- 154 666 3.5 +/- 3.7 40
IFN2 767 +/- 215 686 116.6 +/- 170.0 <1.5
IFN3 977 +/- 254 1000 0.9 +/- 2.5 20
Control C1 1356 +/- 172 708 3.5 +/- 3.7 <1.5
C2 777 +/- 189 313 4.3 +/- 3.6 <1.5
C3 1055 +/- 478 1830 0.8 +/- 0.0 <1.5Retrovirology 2004, 1:29 http://www.retrovirology.com/content/1/1/29
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The absolute numbers of circulating CD8+ T lymphocytes
increased (p < 0.05) transiently during the days following
each infusion of transduced cells, in both groups of
macaques. However, with the exception of these peaks,
absolute numbers of circulating CD8+ T lymphocytes did
not change significantly during the study in any of the ani-
mals of either group (data not shown).
Virological follow-up of animals
We studied the course of SIV infection by determining the
number of copies of SIV proviral DNA per cell, and the
number of copies of SIV viral RNA per ml of blood. SIV
provirus was detected in the PBMCs of all animals in both
groups throughout the study. A transient and significant
(p < 0.05) increase in cellular viral load was observed one
to three weeks after each infusion in macaque IFN1 (Fig.
1B) and in macaques C1, C2 and C3 (Fig. 2B). A similar
transient and significant (p < 0.05) increase in cellular
viral load also occurred one to three weeks after the first
and second infusions in macaque IFN2 and after the third
infusion in macaque IFN3 (Fig. 1A).
Analysis of the number of SIV RNA copies in the plasma
revealed that plasma viremia peaked (p < 0.05) one week
after the first and the third infusions in macaque IFN1
(Fig. 1C), after the first infusion in macaque IFN3 (Fig.
1C) and after the second infusion in macaque C3, (Fig.
2C). The other animals displayed no significant change in
plasma viral load during the course of the experiment.
Discussion
In this study, we assessed the feasibility and efficacy of a
gene therapy method based on the introduction into PBL
of an IFN-β gene resulting in the constitutive production
of low levels of IFN-β, in macaques chronically infected
with SIVmac251. The present work was unable to bring
new lighting on the efficacy of our gene therapy method
since we encountered the problem of disappearence of
transduced cells (control or IFN-β transduced cells) few
days after each infusion.
Throughout the study, significant, transient peaks of cell-
associated and / or plasma viral loads were observed in
Table 2: In vivo follow up of transduced cells in blood. Absolute number of transduced cells per 106 PBMCs were evaluated by 
semiquantitative PCR amplification of IFN-β transgene in the two groups of animals. For in vivo f ollow up of transduced cells in blood 
from macaques, DNA samples of PBMCs were obtained at different dates following infusion of transduced PBL. This table indicates the 
minimum and maximum number of days following the first infusion of transduced cells in which the construct used was still detectable 
in PBMCs. Moreover, maximum transduction rate of PBMCs and detection treshold of the PCR method are indicated in the two groups 
of animals. IFN group is represented by the three macaques that received their own cells transduced by the biologically active construct 
of IFN-β gene whereas the control group is represented by the three macaques that received their own cells transduced by the control 
one. The relative intensity of the signals was compared to serial dilutions of lysate derived from plasmid-transfected cells that contained 
known numbers of IFN-β transgene copy per cell. a Day 0 is the first infusion day, other infusions occured at days 361 and 613. b Absolute 
number of transduced cells was below 10 per 106 PBMCs.
1st infusiona
Days post-1st 
infusion
0 1 4 8 12 14 20 22 25 29 33 52 64 81 95
IFN IFN1 NDb 10 10 10 10 10 NDb NDb NDb NDb NDb NDb NDb NDb NDb
IFN2 NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb
IFN3 NDb 10 10 10 10 10 10 10 10 10 NDb NDb NDb NDb NDb
Contr
ol
C1 NDb 10 10 1000 100 10 10 10 10 10 NDb NDb NDb NDb NDb
C2 NDb 10 10 10 10 10 10 10 10 10 NDb NDb NDb NDb NDb
C3 NDb 1 0 7 0 0 1 01 01 01 01 01 01 0 N D b NDb NDb NDb NDb
2nd infusiona 3rd infusiona
Days post-1st 
infusion
361 364 368 375 382 431 489 613 618 625 632 673 688 744
IFN IFN1 NDb 10 10 10 NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb
IFN2 NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb NDb
IFN3 NDb 10 10 10 NDb NDb NDb NDb 10 10 10 10 NDb NDb
Contr
ol
C1 NDb 10 10 10 NDb NDb NDb NDb 10 10 10 10 NDb NDb
C2 NDb 20 20 20 NDb NDb NDb NDb 10 10 10 10 NDb NDb
C3 NDb 10 10 10 NDb NDb NDb NDb 10 10 10 10 NDb NDbRetrovirology 2004, 1:29 http://www.retrovirology.com/content/1/1/29
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Evolution of immuno-virological parameters in SIVmac251 chronically infected macaques from the IFN group Figure 1
Evolution of immuno-virological parameters in SIVmac251 chronically infected macaques from the IFN group. Immunological 
and virological parameters were followed in macaques that received their own cells transduced by the retroviral construct 
allowing expression of the biologically active form of IFN-β. (A) Absolute number of circulating CD4+ lymphocytes was fol-
lowed by immunophenotyping and flow cytometry. (B) Cell-associated viral load was estimated in PBMCs by a quantitative 
PCR method based on the specific amplification of the SIV gag gene. (C) Plasma viral load was estimated by a quantitative 
branched-DNA method based on the specific amplification of the SIV genome. Y axis split X axis at the first reinfusion date 
(D0) whereas black arrows indicate the second and third reinfusion dates.
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Evolution of immuno-virological parameters in SIVmac251 chronically infected macaques from the control group Figure 2
Evolution of immuno-virological parameters in SIVmac251 chronically infected macaques from the control group. Immunologi-
cal and virological parameters were followed in macaques that received their own cells transduced by the deleted form of the 
retroviral construct. (A) Absolute number of circulating CD4+ lymphocytes was followed by immunophenotyping and flow 
cytometry. (B) Cell-associated viral load was estimated in PBMCs by a quantitative PCR method based on the specific amplifica-
tion of the SIV gag gene. (C) Plasma viral load was estimated by a quantitative branched-DNA method based on the specific 
amplification of the SIV genome. Y axis split X axis at the first reinfusion date (D0) whereas black arrows indicate the second 
and third reinfusion dates.
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most animals a few weeks after the infusion of transduced
cells. These variations may reflect in vivo activation of
viral replication, probably due to the infusion of activated
cells. This phenomenon was also observed after the infu-
sion into SCID mice of transduced human PBLs, resulting
in up-regulation of CCR-5 HIV co-receptor expression in
human CD4+ T cells [27]. Indeed, the SIVmac251 isolate
used in our experiment is a CCR5-dependent virus, and its
replication may have been activated by upregulation of
the CCR-5 coreceptor after infusion. However, gene ther-
apy strategies for the treatment of HIV infection could
only be envisaged in combination with HAART. In this
context, the activation of host virus replication observed
after the infusion of transduced cells would be overcome
by HAART treatment.
The mean rates of transduction of PBL isolated from
macaques chronically infected with SIVmac251 were
10.33 % ± 7.42 % and 17.13 % ± 10.61 % for the MFG-
KbMaIFN-β and MFG-Kb∆MaIFN-β constructs, respec-
tively, which is similar to the transduction efficiency pre-
viously reported for PBLs isolated from healthy non
infected macaques [23,24]. The transduction efficacy for
lymphocytes from healthy donors and HIV-seropositive
patients has also been found to be similar [10], indicating
that chronic infection does not affect the retroviral trans-
duction of lymphocytes.
After the first infusion, small numbers of engineered cells
(control and IFN-β-transduced cells) were detected for
only 29 days. Thus, the persistence of transduced cells in
chronically infected macaques was lower than that previ-
ously reported in non infected macaques, in which IFN-β-
engineered cells were detected for at least 70 days, and for
more than a year after SIVmac251challenge [24]. This
former study indicates also that immune response that
may be induced by mouse cell components or FCS present
in culture medium may not alter persistence of genetically
modified immune cells. We carried out three infusions of
engineered cells and, after each infusion, the engineered
cells disappeared from the bloodstream within a few days.
Poor persistence of circulating engineered cells has been
reported in HIV-infected macaques and in SCID mice, and
has been attributed to the delocalization of circulating
transduced cells in the lymph nodes [28], and intestine
[29]. In our study, we detected no engineered cells in the
lymph nodes or spleen, indicating that the delocalization
of transduced cells to these organs could not account for
the absence of transduced cells in the blood. The short-
term persistence of transduced cells has already been
reported in other studies in which autologous engineered
T cells were cleared rapidly from the bloodstream [30].
However another group reported the persistence of engi-
neered cells for more than 25 weeks (0.1 to 10% of
PBMC) in HIV-infected patients [29,31,32]. They hypoth-
esized that the higher rate of T-cell survival was due to ex
vivo stimulation through CD3 and CD28. Indeed, it has
been demonstrated that the inhibition of HIV replication
in CD3- CD28- stimulated CD4+ cells is due to the pro-
duction of cytokines associated with Th-1 function [33]
and to the downregulation of CCR-5 expression [34].
Thus, in our study, the disappearance of transduced cells
may be due to ConA-stimulation, which may induce
apoptosis in lymphocytes, as previously described [35].
IFN-β-producing cells and cells transduced with the con-
trol vector displayed similar levels of in vivo persistence.
We previously reported higher levels of resistance to HIV
in vitro following the transduction of human CD4+ T cells
[19], human macrophages [36] and macaque PBL [23]
with a construct encoding IFN-β. However, Vieillard et al.
[10] reported inefficient protection of transduced lym-
phocytes against HIV replication in vitro for PBLs isolated
from patients in an advanced state of HIV infection. This
lack of protection probably resulted from the downregu-
lation of interferon alpha/beta receptor expression in
donors with AIDS, leading to hyporesponsiveness to type
I IFN [37]. Thus, although we selected animals with CD4+
cell counts that were still high, the disease may have been
so advanced that transducing PBLs with a construct
encoding IFN-β had little effect, with the engineered lym-
phocytes subjected to the high rate of lymphocyte turno-
ver observed during SIV infection [38,39].
Our previous work with the macaque model encouraged
us to develop low-level autocrine IFN-β production as an
approach to gene therapy for AIDS. The persistence of 1
transduced cell per 103 circulating cells before SIV chal-
lenge was correlated with low plasma virus load and the
maintenance of CD4+ and CD8+ cell counts in macaques
infused with the construct encoding IFN-β [24]. In this
study, performed with animals infected for more than one
year, cells transduced with the IFN-β construct rapidly dis-
appeared from the bloodstream after infusion. This sug-
gests that gene therapy by PBL transduction should be
performed as soon as possible after primary infection. We
are well aware that the number of transduced lym-
phocytes was too small for a major effect in this study and
we believe that further exploration of IFN-β-based anti-
HIV therapy will require the construction of high-titer vec-
tors, with the aim of increasing the proportion of vector-
transduced HIV target cells. An alternative method for
IFN-β gene therapy involves the transduction of CD34+
hematopoietic stem cells. This method has been proposed
for the treatment of HIV infection [40,41]. The transduc-
tion of these cells, which are able to generate all the main
HIV target cells, will increase the proportion of transduced
cells, extend IFN-β production to macrophages and den-
dritic cells, and should facilitate long-term expression of
the therapeutic construct. We have already demonstratedRetrovirology 2004, 1:29 http://www.retrovirology.com/content/1/1/29
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that macrophages transduced with an IFN-β construct dis-
play enhanced HIV resistance, and that HIV transmission
to CD4+ T cells is prevented in IFN-β-transduced dendritic
cells [42]. We intend to investigate the possibility of trans-
ducing hematopoietic stem cells to inhibit viral
replication in macaques chronically infected with
SIVmac251, in the near future.
Methods
Animals
Six male cynomolgus macaques (Macaca fascicularis),
weighing between 3 and 7 kg, and negative for herpes B,
filovirus, STLV-1, SRV-1, SRV-2, SIV, and hepatitis-B were
used in this study. Before all experimental procedures,
animals were anesthetized with chlorhydrate ketamine
(Cenravet, France), and all procedures were conducted
according to European guidelines for animal care (Official
Journal of the European Communities L538, 18 Decem-
ber 1986). Macaques were housed in individual cages in
biosafety level 3 facilities, as required by national regula-
tions (Commission de Génie Génétique, Paris, France).
Viral stock
More than 300 days before infusion with the IFN con-
struct, macaques were intravenously infected with 4 AID50
of a primary, pathogenic SIVmac251 isolate. This virus
stock was obtained by coculturing splenocytes obtained
from an infected rhesus macaque with rhesus macaque
PBMCs (Dr. R.C. Desrosiers, Harvard Medical School, MA,
USA), and was amplified by a second passage on rhesus
PBMCs (prepared and kindly provided by Dr. A.M. Auber-
tin, Université Louis Pasteur, Strasbourg France).
Retroviral vectors
The MFG-KbMaIFN-β retroviral vector used in this study
has been described elsewhere [23]. It contains the
macaque IFN-β coding sequence placed under the control
of a 0.6 kb fragment of the murine H2-Kb gene promoter,
resulting in the continuous production of low levels of a
biologically active macaque IFN-β. The MFG-Kb∆MaIFN-β
retroviral vector used in this study as a control has been
described elsewhere [23]. It contains a macaque IFN-β
coding sequence with a 530 bp deletion, blocking IFN-β
translation, under the control of the same promoter
region. Vectors (MFG-KbMaIFN-β and MFG-Kb∆MaIFN-β
were produced with two Ψ-CRIP packaging clones, each
of which produced 2 × 105 infectious particles per ml,
with no detectable replication-competent helper virus
[23]. The Ψ-CRIP cells were maintained in Dulbecco's
modified Eagle's medium (DMEM, InVitrogen, Grand
Island, New York, USA) supplemented with 10 % heat-
inactivated bovine serum (BS) (InVitrogen) and 0.2 µM
antibiotics (penicillin / streptomycin / neomycin, PSN,
InVitrogen).
Isolation of macaque peripheral blood lymphocytes (PBL)
Three macaques (IFN1, IFN2 and IFN3) received infu-
sions of their own lymphocytes transduced with the bio-
logically active MaIFN-β construct. Another three
macaques (C1, C2, C3) were infused with their own lym-
phocytes transduced with the construct carrying the
deleted form of the MaIFN-β, which cannot produce a
translatable mRNA. We collected about 100 ml of blood
from each macaque into heparin lithium tubes (Greiner,
USA). Buffy coats were obtained by centrifugation (170 g
/ 15 min). Mononuclear cells were collected, and centri-
fuged (400 g / 30 min) on a Ficoll density gradient (Euro-
bio, Les Ulis, France). Plasma and erythrocytes, diluted 1
in 2 with 0.9% NaCl (InVitrogen), were washed and used
immediately for infusion into the macaques.
Transduction of macaque PBLs
Isolated PBMCs (106 cells per ml) were activated by incu-
bation for three days in RPMI-1640 medium, 10 % fetal
calf serum (FCS), 2 mM L-glutamine (Bœhringer Man-
nheim, Mannheim, Germany), 0.2 µM antibiotics (peni-
cillin / streptomycin / neomycin), 5 µg / ml concanavalin
A (InVitrogen). Activated PBL were resuspended in trans-
duction medium consisting ofn 45 % DMEM, 45 %
IMDM (InVitrogen), 5 % FCS, 5 % BS, 4 µg / ml pro-
tamine sulfate (Sigma, Saint Louis, USA) and 20 IU / ml
recombinant human (rHu) IL-2 (Bœhringer Mannheim).
Cells were transduced by coculture for three days with
subconfluent Ψ-CRIP packaging cells. At the end of the
coculture period, the various cell populations were
transferred twice to other culture plates to eliminate any
residual adherent packaging cells. Transduced lym-
phocytes were washed, resuspended in 1× PBS at a con-
centration of 107 cells / ml, and injected intravenously
into macaques. Transduction efficacy was estimated with
transduced PBLs maintained in culture for 3 days.
Evaluation of the transduction rate
DNA was extracted from macaque PBMCs and the
amount used for each sample was normalized based on
data for amplification of the β-globin gene, using 5'-
ACCATGGTGCTGTCTCCTGC-3' as sense primer, and 5'-
CATGGCCACGAGGCTCCA-3' as an antisense primer.
Both retroviral sequences were detected, using 5'-
GTTCAGGCAAAGTCTTAGTC-3' as the sense primer,
binding in the H2-Kb  gene promoter and 5'-TGAA-
GATCTCCTAGCCTGT-3 as the antisense primer, binding
in the macaque IFN-β coding sequence. These primers
amplified a 870-bp fragment from the MFG-KbMaIFN-β
vector, and a 340-bp fragment from the MFG-Kb∆MaIFN-
 vector The PCR amplification products were identified
by dot-blot hybridization with an IFN-β probe, and quan-
tified with a PhosphorImager (Molecular Dynamics, Sev-
enoaks, England, UK), as previously described [19].
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Relative signal intensity was compared with the signal
intensity of serial dilutions of lysate derived from plas-
mid-transfected cells containing known numbers of trans-
gene copies per cell. The detection threshold of the PCR
assay used was estimated and found to be one copy of the
IFN-β gene per 105 cells.
Hematological and immunological follow-up of infused 
macaques
All infused animals were followed during the months pre-
ceding the study, and for more than 700 days after the first
autologous infusion. We carried out hematological analy-
sis, and monitored weight, rectal temperature, and levels
of lymphocytes transduced with the IFN-β construct.
Blood formula and blood cell counts were determined
with an automated hemocytometer (Coulter Corporation,
Miami, USA). Axillary lymph nodes and spleens were
removed from animals and ground in 1× PBS using a Pot-
ter homogenizer. Lymph nodes and splenic mononuclear
cells (LNMC, SMC) were then collected and centrifuged
(400 g / 30 min) on a Ficoll cushion (Eurobio, Les Ulis,
France). DNA extraction and evaluation of in the rate of
transduction of LNMC and SMC were performed as previ-
ously described.
In vivo immunological follow-up of macaques receiving 
infusions
We estimated the proportions of the various subtypes of
circulating PBMCs by direct immunofluorescence assay
(anti-CD3 clone FN18, Biosource International, CA,
USA), anti-CD4 clone Leu 3a PE (Becton Dickinson, San
Jose, Mountain View, CA, USA), anti-CD8 clone Leu 2a
FITC (Becton Dickinson) antibodies and IgG isotypic con-
trols (Immunotech, Marseille, France), and flow cytome-
try (Becton Dickinson). We used specific software
(CellQuest, Becton Dickinson) as previously described
[25] for the analysis.
Sorting of CD4+ and CD8+ circulating lymphocytes
Mononuclear cells isolated on Ficoll-Hypaque were posi-
tively separated using CD4-specific and CD8-specific
immunomagnetic microbeads (MiniMACS, Miltenyi,
Stadt, Germany) according to manufacturer's instructions.
Subset purity was evaluated by flow cytometry, using sec-
ondary anti-CD4 clone OKT4-PE (Dako, Glostrup, Den-
mark) and anti-CD8 clone DK25-FITC (Dako) antibodies.
The rates of transduction of the sorted CD4+ and CD8+
lymphocytes were evaluated, as described above.
Plasma and cell-associated viral load
Levels of SIV RNA in plasma were determined with the
SIVmac-branched-DNA assay, using a detection threshold
of 1,500 mEq per milliliter of plasma (Chiron Diagnos-
tics, Amsterdam, The Netherlands). DNA was extracted
from PBMCs with an extraction kit (Roche Diagnostics
GmbH, Mannheim, Germany). Levels of SIV DNA in cells
were determined using a two-step PCR method with two
external  gag-specific primers (1386-5': GAAACTAT-
GCCAAAAACAAGT and 2129-5': TAATCTAGCCTTCT-
GTCCTGG) and two internal gag-specific primers (1731N
5': CCGTCAGGATCAGATATTGCAGGAA and 2042C 5':
CACTAGCTTGCAATCTGGGTT), as previously described
[26].
Statistical analysis
Statistical significance was determined by paired or
unpaired non parametric Wilcoxon and Mann-Whitney
tests adapted for small samples.
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